Skip to main content
CodeRx
Open menu
↑↓ move↵ open CodeRx

C-code: Hospital outpatient (OPPS) codes Hospital outpatient (OPPS) codes

622 codes

Billing context

C-codes are temporary codes for hospital outpatient use under the Medicare Outpatient Prospective Payment System, including pass-through drugs and biologicals (many in C9xxx) and devices. They are generally not reported by physician offices; other payers may not recognize them.
C-codes, page 4 of 7
CodeLong descriptorPayment limit (Q4 2026)AddedStatus
C9014Injection, cerliponase alfa, 1 mg—Jan 1, 2018Ended Dec 31, 2018
C9015Injection, c-1 esterase inhibitor (human), haegarda, 10 units—Jan 1, 2018Ended Dec 31, 2018
C9016Injection, triptorelin extended release, 3.75 mg—Jan 1, 2018Ended Dec 31, 2018
C9021Injection, obinutuzumab, 10 mg—Apr 1, 2014Ended Dec 31, 2014
C9022Injection, elosulfase alfa, 1mg—Jul 1, 2014Ended Dec 31, 2014
C9023Injection, testosterone undecanoate, 1 mg—Oct 1, 2014Ended Dec 31, 2014
C9024Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine—Jan 1, 2018Ended Dec 31, 2018
C9025Injection, ramucirumab, 5 mg—Oct 1, 2014Ended Dec 31, 2015
C9026Injection, vedolizumab, 1 mg—Oct 1, 2014Ended Dec 31, 2015
C9027Injection, pembrolizumab, 1 mg—Jan 1, 2015Ended Dec 31, 2015
C9028Injection, inotuzumab ozogamicin, 0.1 mg—Jan 1, 2018Ended Dec 31, 2018
C9029Injection, guselkumab, 1 mg—Jan 1, 2018Ended Dec 31, 2018
C9030Injection, copanlisib, 1 mg—Jul 1, 2018Ended Dec 31, 2018
C9031Lutetium lu 177, dotatate, therapeutic, 1 mci—Jul 1, 2018Ended Dec 31, 2018
C9032Injection, voretigene neparvovec-rzyl, 1 billion vector genome—Jul 1, 2018Ended Dec 31, 2018
C9033Injection, fosnetupitant 235 mg and palonosetron 0.25 mg—Oct 1, 2018Ended Dec 31, 2018
C9034Injection, dexamethasone 9%, intraocular, 1 mcg—Oct 1, 2018Ended Dec 31, 2018
C9035Injection, aripiprazole lauroxil (aristada initio), 1 mg—Jan 1, 2019Ended Sep 30, 2019
C9036Injection, patisiran, 0.1 mg—Jan 1, 2019Ended Sep 30, 2019
C9037Injection, risperidone (perseris), 0.5 mg—Jan 1, 2019Ended Sep 30, 2019
C9038Injection, mogamulizumab-kpkc, 1 mg—Jan 1, 2019Ended Sep 30, 2019
C9039Injection, plazomicin, 5 mg—Jan 1, 2019Ended Sep 30, 2019
C9040Injection, fremanezumab-vfrm, 1mg—Apr 1, 2019Ended Sep 30, 2019
C9041Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mg—Apr 1, 2019Ended Jun 30, 2020
C9042Injection, bendamustine hcl (belrapzo), 1 mg—Apr 1, 2019Ended Jun 30, 2019
C9043Injection, levoleucovorin, 1 mg—Apr 1, 2019Ended Dec 31, 2019
C9044Injection, cemiplimab-rwlc, 1 mg—Apr 1, 2019Ended Sep 30, 2019
C9045Injection, moxetumomab pasudotox-tdfk, 0.01 mg—Apr 1, 2019Ended Sep 30, 2019
C9046Cocaine hydrochloride nasal solution (goprelto), 1 mg—Apr 1, 2019Ended Sep 30, 2026
C9047Injection, caplacizumab-yhdp, 1 mg—Jul 1, 2019Active
C9048Dexamethasone, lacrimal ophthalmic insert, 0.1 mg—Jul 1, 2019Ended Sep 30, 2019
C9049Injection, tagraxofusp-erzs, 10 mcg—Jul 1, 2019Ended Sep 30, 2019
C9050Injection, emapalumab-lzsg, 1 mg—Jul 1, 2019Ended Sep 30, 2019
C9051Injection, omadacycline, 1 mg—Jul 1, 2019Ended Sep 30, 2019
C9052Injection, ravulizumab-cwvz, 10 mg—Jul 1, 2019Ended Sep 30, 2019
C9053Injection, crizanlizumab-tmca, 1 mg—Apr 1, 2020Ended Jun 30, 2020
C9054Injection, lefamulin (xenleta), 1 mg—Jan 1, 2020Ended Jun 30, 2020
C9055Injection, brexanolone, 1mg—Jan 1, 2020Ended Sep 30, 2020
C9056Injection, givosiran, 0.5 mg—Apr 1, 2020Ended Jun 30, 2020
C9057Injection, cetirizine hydrochloride, 1 mg—Apr 1, 2020Ended Jun 30, 2020
C9058Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mg—Nov 15, 2019Ended Jun 30, 2020
C9059Injection, meloxicam, 1 mg—Jul 1, 2020Ended Sep 30, 2020
C9060Fluoroestradiol f18, diagnostic, 1 mci—Oct 1, 2020Ended Dec 31, 2020
C9061Injection, teprotumumab-trbw, 10 mg—Jul 1, 2020Ended Sep 30, 2020
C9062Injection, daratumumab 10 mg and hyaluronidase-fihj—Oct 1, 2020Ended Dec 31, 2020
C9063Injection, eptinezumab-jjmr, 1 mg—Jul 1, 2020Ended Sep 30, 2020
C9064Mitomycin pyelocalyceal instillation, 1 mg—Oct 1, 2020Ended Dec 31, 2020
C9065Injection, romidepsin, non-lyophilized (e.g. liquid), 1mg—Oct 1, 2020Ended Sep 30, 2021
C9066Injection, sacituzumab govitecan-hziy, 2.5 mg—Oct 1, 2020Ended Dec 31, 2020
C9067Gallium ga-68, dotatoc, diagnostic, 0.01 mci—Oct 1, 2020Active
C9068Copper cu-64, dotatate, diagnostic, 1 millicurie—Jan 1, 2021Ended Mar 31, 2021
C9069Injection, belantamab mafodontin-blmf, 0.5 mg—Jan 1, 2021Ended Mar 31, 2021
C9070Injection, tafasitamab-cxix, 2 mg—Jan 1, 2021Ended Mar 31, 2021
C9071Injection, viltolarsen, 10 mg—Jan 1, 2021Ended Mar 31, 2021
C9072Injection, immune globulin (asceniv), 500 mg—Jan 1, 2021Ended Mar 31, 2021
C9073Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose—Jan 1, 2021Ended Mar 31, 2021
C9074Injection, lumasiran, 0.5 mg—Apr 1, 2021Ended Jun 30, 2021
C9075Injection, casimersen, 10 mg—Jul 1, 2021Ended Sep 30, 2021
C9076Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose—Jul 1, 2021Ended Sep 30, 2021
C9077Injection, cabotegravir and rilpivirine, 2mg/3mg—Jul 1, 2021Ended Sep 30, 2021
C9078Injection, trilaciclib, 1 mg—Jul 1, 2021Ended Sep 30, 2021
C9079Injection, evinacumab-dgnb, 5 mg—Jul 1, 2021Ended Sep 30, 2021
C9080Injection, melphalan flufenamide hydrochloride, 1 mg—Jul 1, 2021Ended Sep 30, 2021
C9081Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose—Oct 1, 2021Ended Dec 31, 2021
C9082Injection, dostarlimab-gxly, 100 mg—Oct 1, 2021Ended Dec 31, 2021
C9083Injection, amivantamab-vmjw, 10 mg—Oct 1, 2021Ended Dec 31, 2021
C9084Injection, loncastuximab tesirine-lpyl, 0.1 mg—Oct 1, 2021Ended Mar 31, 2022
C9085Injection, avalglucosidase alfa-ngpt, 4 mg—Jan 1, 2022Ended Mar 31, 2022
C9086Injection, anifrolumab-fnia, 1 mg—Jan 1, 2022Ended Mar 31, 2022
C9087Injection, cyclophosphamide, (auromedics), 10 mg—Jan 1, 2022Ended Mar 31, 2022
C9088Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg—Jan 1, 2022Ended Sep 30, 2025
C9089Bupivacaine, collagen-matrix implant, 1 mg—Jan 1, 2022Ended Dec 31, 2025
C9090Injection, plasminogen, human-tvmh, 1 mg—Apr 1, 2022Ended Jun 30, 2022
C9091Injection, sirolimus protein-bound particles, 1 mg—Apr 1, 2022Ended Jun 30, 2022
C9092Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg—Apr 1, 2022Ended Jun 30, 2022
C9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg—Apr 1, 2022Ended Jun 30, 2022
C9094Inj, sutimlimab-jome, 10 mg—Jul 1, 2022Ended Sep 30, 2022
C9095Inj, tebentafusp-tebn, 1 mcg—Jul 1, 2022Ended Sep 30, 2022
C9096Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram—Jul 1, 2022Ended Sep 30, 2022
C9097Inj, faricimab-svoa, 0.1 mg—Jul 1, 2022Ended Sep 30, 2022
C9098Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose—Jul 1, 2022Ended Sep 30, 2022
C9101Injection, oliceridine, 0.1 mg—Oct 1, 2022Active
C9113Injection, pantoprazole sodium, per vial—Jan 1, 2002Ended Jun 30, 2024
C9121Injection, argatroban, per 5 mg—Jan 1, 2003Ended Dec 31, 2016
C9122Mometasone furoate sinus implant, 10 micrograms (sinuva)—Jul 1, 2020Ended Mar 31, 2021
C9132Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity—Oct 1, 2013Ended Jun 30, 2021
C9133Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.—Jan 1, 2014Ended Dec 31, 2014
C9134Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.—Jul 1, 2014Ended Dec 31, 2014
C9135Factor ix (antihemophilic factor, recombinant), alprolix, per i.u.—Oct 1, 2014Ended Dec 31, 2014
C9136Injection, factor viii, fc fusion protein, (recombinant), per i.u.—Jan 1, 2015Ended Mar 31, 2015
C9137Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.—Apr 1, 2016Ended Dec 31, 2016
C9138Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.—Apr 1, 2016Ended Dec 31, 2016
C9139Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.—Oct 1, 2016Ended Dec 31, 2016
C9140Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.—Jan 1, 2017Ended Dec 31, 2017
C9141Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.—Apr 1, 2019Ended Jun 30, 2019
C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg—Oct 1, 2022Ended Dec 31, 2022
C9143Cocaine hydrochloride nasal solution (numbrino), 1 mg—Jan 1, 2023Active
C9144Injection, bupivacaine (posimir), 1 mg—Jan 1, 2023Active
C9145Injection, aprepitant, (aponvie), 1 mg—Apr 1, 2023Ended Mar 31, 2026
C9146Injection, mirvetuximab soravtansine-gynx, 1 mg—Apr 1, 2023Ended Jun 30, 2023